Clinical TrialMay 6, 2026, 08:03 AM
IN8bio to Present New Clinical Data at ASCO, Host R&D Day
AI Summary
IN8bio, Inc. announced a series of presentations at major medical and scientific conferences in May and June 2026, including new clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting. The company will also host a Research and Development (R&D) Day on May 21, 2026, to highlight advancements across its gamma-delta T cell pipeline, including its novel T cell engager (TCE) and clinical programs. These events will showcase progress in their TCE program and translational advances supporting observed survival benefits in glioblastoma patients.
Key Highlights
- IN8bio will host an R&D Day on May 21, 2026, showcasing its T cell engager (TCE) platform and GBM clinical program.
- New clinical data from the Phase I study of INB-200 in newly diagnosed glioblastoma (GBM) will be presented at ASCO on June 1, 2026.
- Two poster presentations on gamma-delta T cell therapy in glioblastoma and operational efficiency are scheduled for ISCT on May 7, 2026.
- An oral presentation challenging the glioblastoma status quo with gamma-delta T cells will be given at ASGCT on May 14, 2026.
- Presentations will highlight progress in the novel TCE program and translational advances in the clinical program for GBM patients.
Price Impact
More from INAB